Ulinastatin - Techpool

Drug Profile

Ulinastatin - Techpool

Alternative Names: Techpool Roan

Latest Information Update: 12 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Guangdong Techpool Bio-Pharma
  • Class Anti-inflammatories; Cytoprotectives; Glycoproteins; Uroprotectives
  • Mechanism of Action Serine protease inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pancreatitis; Vascular disorders
  • Phase I Severe acute respiratory syndrome

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Jan 2016 TechPool and Peking Union Medical College Hospital plans a phase IV trial for Sepsis and Septic shock in China (NCT02647554)
  • 16 Jul 2014 Phase-I clinical trials in Severe acute respiratory syndrome (In volunteers) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top